Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jan-Peer Elshoff"'
Autor:
Ronit Pressler, Geraldine Boylan, Eugene Dempsey, Kerstin Alexandra Klotz, Walter Krauwinkel, Edgar Will, Diego Morita, Florin Floricel, Jan‐Peer Elshoff, John van denAnker
Publikováno v:
Epilepsia Open, Vol 9, Iss 2, Pp 522-533 (2024)
Abstract Objective To evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) in neonates with repeated electroencephalographic seizures not controlled with previous antiseizure medications (ASMs). Methods Phase 2/3, multic
Externí odkaz:
https://doaj.org/article/8137ef2a8dbb4c9a914a2a6bdb5fe170
Autor:
Thomas Bast, Anne‐Liv Schulz, Florin Floricel, Diego Morita, Jody M. Cleveland, Jan‐Peer Elshoff
Publikováno v:
Epilepsia Open, Vol 7, Iss 4, Pp 588-597 (2022)
Abstract Objective Despite introduction of several antiseizure medications over the past two decades, treatment options for childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE) remain limited. We report the innovative adaptive design
Externí odkaz:
https://doaj.org/article/7812ba6767774e938183b18d35f90001
Autor:
Jan-Peer Elshoff, Sofia Fleyshman, Christine De La Loge, Najla Dickson, Christoph Reichel, Florin Floricel, Patricia Smeyers
Publikováno v:
Thursday, April 27.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fc2abe9115354557efbecb7b57a203d
https://doi.org/10.1212/wnl.0000000000201877
https://doi.org/10.1212/wnl.0000000000201877
Autor:
Mark Kristof Farkas, Harriet Kang, Andras Fogarasi, Ali Bozorg, Gareth D. James, Walter Krauwinkel, Diego Morita, Edgar Will, Jan‐Peer Elshoff
Publikováno v:
Epilepsia. 63(4)
To evaluate the pharmacokinetics, safety, and tolerability of brivaracetam (BRV) as 15-min intravenous (IV) infusion and bolus (≤2-min injection).EP0065 (ClinicalTrials.gov: NCT03405714) was a Phase 2, multicenter, open-label trial in patients ≥1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::175ac6ee4eff10cd7327ad231205b62e
https://pubmed.ncbi.nlm.nih.gov/35196395
https://pubmed.ncbi.nlm.nih.gov/35196395
Autor:
Lars Bauer, Christoph Arth, Miriam Schmid, Jan-Peer Elshoff, Michael Komenda, Marcus Brunnert, Lars Timmermann
Rotigotine transdermal patch is approved for the treatment of early and advanced idiopathic Parkinson’s disease (PD) and moderate-to-severe idiopathic restless legs syndrome (RLS). A cold chain manufacturing and distribution process was temporarily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba9b103ebac97a220ab81b910a269e8
Autor:
Erwin Schollmayer, John D. Hudson, Jan-Peer Elshoff, Daniel L. Picchietti, Francisco Ramirez, Kimberly Doggett, Kimberly Moran, Arthur S. Walters, Keith Ridel, M. Oortgiesen
Publikováno v:
Sleep Medicine. 32:48-55
Objective To investigate the pharmacokinetics (PK) of rotigotine transdermal system in adolescents with moderate-to-severe idiopathic restless legs syndrome (RLS). Methods This multicenter, open-label, dose-escalation study enrolled patients ≥13 to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96f0deb1f0a5eaf923f108399dfd33ad
https://doi.org/10.1016/j.sleep.2016.04.012
https://doi.org/10.1016/j.sleep.2016.04.012
Publikováno v:
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 25
To evaluate long-term safety and tolerability of adjunctive brivaracetam (BRV) in children with epilepsy.This was an interim analysis (cut-off March 15, 2017) of pooled data from two open-label, single-arm, multicentre trials. N01263 (NCT00422422) wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde6469ff43f747799eeee69aa0026e6
https://pubmed.ncbi.nlm.nih.gov/31810577
https://pubmed.ncbi.nlm.nih.gov/31810577
Publikováno v:
Current medical research and opinion. 34(7)
Objective: In patch-based transdermal drug delivery, adhesiveness is critical for safe and effective treatment, especially in Parkinson’s disease (PD) where excessive sweating is common. This study compared the adhesiveness of two transdermal patch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6935f1cacbe6c8faaba6b9ae6a4f9b9f
https://pubmed.ncbi.nlm.nih.gov/29461870
https://pubmed.ncbi.nlm.nih.gov/29461870
Autor:
Kyung Sang Yu, Marina Braun, Jens Otto Andreas, In-Jin Jang, Jung-Ryul Kim, Bo Hyung Kim, Willi Cawello, Jan Peer Elshoff, Kyoung Soo Lim
Publikováno v:
Clinical Therapeutics. 37:902-912
Purpose Rotigotine, a nonergolinic dopamine receptor agonist, is a once-daily transdermal patch developed for the treatment of Parkinson's disease and restless legs syndrome. The objective of the present study was to determine the pharmacokinetic cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cc71b72e398ab09ba3df98d91c00819
https://doi.org/10.1016/j.clinthera.2015.01.013
https://doi.org/10.1016/j.clinthera.2015.01.013
Autor:
Takeuchi Masahiro, Tomoo Funaki, Junji Ikeda, Willi Cawello, Marina Braun, Jan-Peer Elshoff, Seong Ryul Kim
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 41:353-362
Rotigotine is a dopamine receptor agonist indicated for the treatment of Parkinson's disease and moderate-to-severe restless legs syndrome. Continuous transdermal delivery of rotigotine via a silicon-based patch maintains stable plasma concentrations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3ff2fa46886360f63c10027b3d78acc
https://doi.org/10.1007/s13318-015-0273-6
https://doi.org/10.1007/s13318-015-0273-6